** Shares of regenerative medicine company Orthocell OCC.AX rise 7.8% to A$1.390, set for biggest one-day gain since April 10
** Co says it has received regulatory approval to commence sales for its nerve repair product, Remplir, from the Food and Drug Administration in Thailand
** Stock on track for third consecutive session of gains
** Stock up 2.6% YTD, including current session's moves
(Reporting by Manasi Dasa in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。